WallStreetZenWallStreetZen

NASDAQ: BCEL
Atreca Inc Stock Forecast, Predictions & Price Target

Analyst price target for BCEL

Based on 2 analysts offering 12 month price targets for Atreca Inc.
Min Forecast
$1.00+314.94%
Avg Forecast
$1.00+314.94%
Max Forecast
$1.00+314.94%

Should I buy or sell BCEL stock?

Based on 2 analysts offering ratings for Atreca Inc.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
2 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BCEL stock forecasts and price targets.

BCEL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-08-14
lockedlocked$00.00+00.00%2023-08-11

1 of 1

Forecast return on equity

Is BCEL forecast to generate an efficient return?
Company
N/A
Industry
-0.69%
Market
30.36%

Forecast return on assets

Is BCEL forecast to generate an efficient return on assets?
Company
N/A
Industry
-0.29%

BCEL revenue forecast

What is BCEL's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$50.0M
Avg 2 year Forecast
$50.0M
Avg 3 year Forecast
$50.0M

BCEL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BCEL$0.24$1.00+314.94%Hold
ARAV$0.13$0.25+92.31%Hold
PSTV$2.12$8.00+277.36%Buy
TNXP$0.40$8.00+1,910.05%Strong Buy
GOVX$0.36$8.00+2,122.22%Buy

Atreca Stock Forecast FAQ

Is Atreca Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: BCEL) stock is to Hold BCEL stock.

Out of 2 analysts, 0 (0%) are recommending BCEL as a Strong Buy, 0 (0%) are recommending BCEL as a Buy, 2 (100%) are recommending BCEL as a Hold, 0 (0%) are recommending BCEL as a Sell, and 0 (0%) are recommending BCEL as a Strong Sell.

If you're new to stock investing, here's how to buy Atreca stock.

What is BCEL's revenue growth forecast for 2024-2027?

(NASDAQ: BCEL) Atreca's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.66%.

Atreca's revenue in 2023 is $0.On average, 1 Wall Street analysts forecast BCEL's revenue for 2024 to be $1,981,203,750, with the lowest BCEL revenue forecast at $1,981,203,750, and the highest BCEL revenue forecast at $1,981,203,750. On average, 1 Wall Street analysts forecast BCEL's revenue for 2025 to be $1,981,203,750, with the lowest BCEL revenue forecast at $1,981,203,750, and the highest BCEL revenue forecast at $1,981,203,750.

In 2027, BCEL is forecast to generate $1,981,203,750 in revenue, with the lowest revenue forecast at $1,981,203,750 and the highest revenue forecast at $1,981,203,750.

What is BCEL's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: BCEL) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.29%.

What is BCEL's Price Target?

According to 2 Wall Street analysts that have issued a 1 year BCEL price target, the average BCEL price target is $1.00, with the highest BCEL stock price forecast at $1.00 and the lowest BCEL stock price forecast at $1.00.

On average, Wall Street analysts predict that Atreca's share price could reach $1.00 by Aug 14, 2024. The average Atreca stock price prediction forecasts a potential upside of 314.94% from the current BCEL share price of $0.24.

What is BCEL's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: BCEL) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.